Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* 18 years of age or older with diabetic macular edema;~* Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or worse);~* Visual acuity in other eye no worse than 20/200~Key Exclusion Criteria:~* Known anticipated need for ocular surgery within next 12 months;~* History of glaucoma or current high eye pressure requiring more than 1 medication;~* Uncontrolled systemic disease;~* Known steroid-responder;~* Use of systemic steroids;~* Use of Warfarin/Heparin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone 700 μg (Type: EXPERIMENTAL): 700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
- Dexamethasone 350 μg (Type: EXPERIMENTAL): 350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
- Sham (Type: SHAM_COMPARATOR): Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).